Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in exudative age-related macular degeneration
NL-OMON20009Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in exudative macular degeneration, sponsored by Erasmus MC. Primary endpoint: Absolute change in visual acuity versus baseline. Started Jan 2006; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON20009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20009.